The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 06, 2018

Filed:

Jul. 31, 2014
Applicant:

Regents of the University of Minnesota, Minneapolis, MN (US);

Inventors:

Ronald A. Siegel, Minneapolis, MN (US);

James Cloyd, Minneapolis, MN (US);

Tate Winter, Minneapolis, MN (US);

Mamta Kapoor, Minneapolis, MN (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/43 (2006.01); A61K 38/48 (2006.01); A61K 38/46 (2006.01); A61K 47/48 (2006.01); A61K 31/5513 (2006.01); A61K 31/675 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/4166 (2006.01);
U.S. Cl.
CPC ...
A61K 38/482 (2013.01); A61K 9/006 (2013.01); A61K 9/0043 (2013.01); A61K 9/0073 (2013.01); A61K 9/20 (2013.01); A61K 9/2004 (2013.01); A61K 9/48 (2013.01); A61K 31/4166 (2013.01); A61K 31/5513 (2013.01); A61K 31/675 (2013.01); A61K 38/465 (2013.01); A61K 38/4813 (2013.01); A61K 47/48138 (2013.01); C12Y 301/03001 (2013.01); C12Y 304/21063 (2013.01);
Abstract

The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine.


Find Patent Forward Citations

Loading…